^
    Back
    Association details:
    Biomarker:BRCA wild-type
    Cancer:Ovarian Cancer
    Drug:Rubraca (rucaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Maintenance Therapy….Rucaparib added as an option for BRCA1/2 wild-type or unknown and germline or somatic BRCA1/2 mutation.
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Cureus
    Title:

    Rucaparib as a Salvage Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma: A Case Report

    Published date:
    10/17/2022
    Excerpt:
    The present case report deals with treating one such platinum-sensitive first relapse of high-grade serous ovarian carcinoma with a poly (ADP-ribose) polymerase (PARP) inhibitor. Here, rucaparib, one of the Food and Drug Administration (FDA)-approved PARP inhibitors, was used to treat platinum-sensitive relapse in a patient with germline breast cancer (BRCA) negative ovarian cancer. The patient showed a complete response to the treatment and was in remission for around 11 months with only one dose reduction and no blood transfusion.
    DOI:
    10.7759/cureus.30405